2018 Competitor Analysis: hTERT-Targeted Immunotherapy – ResearchAndMarkets.com

Analysis: hTERT-Targeted Immunotherapy”
report has been added
to ResearchAndMarkets.com’s offering.

This Competitive Intelligence report analyzes the competitive field of
hTERT-Targeted Immunotherapies as of June 2018 in a tabulated format
with structured listings of industry-relevant data.

The report includes a compilation of currently active projects in
research and development of vaccines, Cytotoxic T-Lymphocytes (CTLs),
small molecules and oncolytic viruses targeting human telomerase reverse
transcriptase (hTERT). In addition, the report lists company- and
institution-specific R&D pipelines of hTERT-Targeted Immunotherapies.

Human telomerase reverse transcriptase (hTERT), a catalytic subunit of
telomerase, is one of two essential components of telomerase, an enzyme
complex that generates and maintains telomeres. Telomerase is expressed
mainly in embryonic and adult stem cells.

Telomere biology has recently been implicated in the pathogenesis of a
variety of diseases, and mutations in telomerase components result in a
predisposition to solid malignancies. More recent findings show that
TERT is not only expressed in late stage primary tumor cells and
metastatic cells, but also expressed in incipient cancer stem cells
and/or tumor-initiating cells, indicating that TERT has essential roles
at every stage of tumorigenesis.

The intracellular protein hTERT is widely overexpressed in human cancers
including prostate cancer. Along with its regulation of the telomere,
hTERT was also shown to regulate various signal transduction mechanisms
involving DNA damage response, cell cycle checkpoint, and apoptosis. The
majority of human solid tumors display telomerase activity, which was
found to be well correlated with hTERT expression, and hTERT inhibition
led to reduced telomerase activity and telomere length.

Competitor projects are listed in a tabular format providing
information on:

  • Drug Codes
  • Target/Mechanism of Action
  • Class of Compound
  • Company
  • Product Category
  • Indication
  • R&D Stage
  • Additional comments with a hyperlink leading to the source of

Key Topics Covered

1. hTERT-Targeted Immunotherapy

  • hTERT-Selective Cancer Vaccines
  • hTERT-Specific, Multi-Target Cancer Vaccines
  • hTERT-Targeted Adoptive Cell Therapy
  • Other hTERT-Targeted Immunotherapies

2. Corporate & Institutional hTERT Immunotherapy R&D Pipelines

For more information about this report visit https://www.researchandmarkets.com/research/vc2jlh/2018_competitor?w=4


Laura Wood, Senior Manager
E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call
For GMT Office Hours Call +353-1-416-8900
Topics: Oncology